An opinion article published on Fox News warns that Chinese chemical manufacturers are shipping an experimental, non-FDA-approved injectable drug called retatrutide ("reta") directly to American consumers seeking weight-loss treatments. The piece argues this mirrors the fentanyl crisis, in which Chinese suppliers provided precursor chemicals to cartels, and warns that the same illicit infrastructure – customs fraud, concealed shipments and US-based middlemen – is now being repurposed to exploit demand for GLP-1-style weight-loss drugs, raising national security concerns beyond public health.

The article cites blockchain analysis firms Chainalysis and TRM Labs, which reportedly traced proceeds from US peptide sales back to Chinese manufacturers previously linked to synthetic opioid production, and note some of these firms shifting into the "peptide business." It describes vendors disguising retatrutide with coded names such as "GLP-3 RT" and labelling packages "for research use only" while still supplying dosing instructions and syringes. It also references a Customs and Border Protection operation in Cincinnati that seized more than 300 master cartons from China containing roughly 5,000 individual peptide shipments, including retatrutide, and calls for the pipeline to be shut down as a matter of national security rather than treated purely as a pharmaceutical issue.